Panbela Therapeutics Current ratio
What is the Current ratio of Panbela Therapeutics?
The Current ratio of Panbela Therapeutics Inc. is 0.21
What is the definition of Current ratio?
Current ratio is a liquidity ratio that measures whether or not a company has enough resources to meet its short-term obligations.
mrq (most recent quarter)
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with current ratio similar to Panbela Therapeutics
- Integrated Finl Hldgs Inc has Current ratio of 0.21
- Westpac Banking has Current ratio of 0.21
- SugarBud Craft Growers has Current ratio of 0.21
- AllianceBernstein National Municipal Income Fund Inc has Current ratio of 0.21
- Cannabis Strategic Ventures has Current ratio of 0.21
- Guangzhou Rural Commercial Bank Co has Current ratio of 0.21
- Panbela Therapeutics has Current ratio of 0.21
- BlackRock Muni Quality Fund II Inc has Current ratio of 0.21
- Rainy Mountain Royalty has Current ratio of 0.21
- Cullen/Frost Bankers has Current ratio of 0.21
- Videocon Industries has Current ratio of 0.21
- Home Invest Belgium S.A has Current ratio of 0.21
- Cannabis Global, Inc has Current ratio of 0.21